About Ang Lifesciences India Limited
Data last updated: 14 July 2026
Ang Lifesciences India Limited is a public limited company based in Amritsar, Punjab, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 14 June 2006, the company has been in operation for over 20 years.
Registered with ROC Chandigarh under CIN L24230PB2006PLC030341. Listed on BSE: 540694.
Capital: an authorised share capital of ₹14 Cr and a paid-up capital of ₹13.06 Cr. Formerly known as Ang Lifesciences Private Limited and Ang Lifesciences India Limited. It is led by directors including Sukhpal Singh and Chetna.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Amritsar, Punjab.
As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹92.89 Cr, a growth of 0.05% compared to the previous year. The net worth stands at ₹52.89 Cr (down 17.33% YoY). Total assets are valued at ₹208.95 Cr (down 8.99% YoY).
The company has a workforce of approximately 459 employees as per the latest available data. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Ang Lifesciences. As per MCA filings, the company has open charges of ₹81.62 Cr and satisfied charges of ₹13.33 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website anglifesciences.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered AddressDarbara Complex Sco 113 First Floor District Shopping Centre B Block Ranjit, Avenue, Amritsar, Punjab, India – 143001
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Ang Lifesciences India Limited
Ang Lifesciences India Limited has undergone 3 name changes throughout its history. The company was previously known as Ang Lifesciences Private Limited, Ang Lifesciences India Limited, and Ang Lifesciences India Private Limited. The current legal name is Ang Lifesciences India Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Ang Lifesciences India Limited | Current |
| Ang Lifesciences Private Limited | Previous |
| Ang Lifesciences India Limited | Previous |
| Ang Lifesciences India Private Limited | Previous |
CIN History of Ang Lifesciences India Limited
Ang Lifesciences India Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230PB2006PLC030341, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230PB2006PLC030341 | Current |
| U24230PB2006PTC030341 | Previous |
| U24230PB2006PLC030341 | Previous |
Associated Brands with Ang Lifesciences India Limited
Ang Lifesciences India Limited operates one associated brand: ANG Lifesciences. These brands represent Ang Lifesciences India Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Dry Powder Injectables are contract manufactured and exported. | anglifesciences.com |
Competitors & Alternatives of Ang Lifesciences India Limited
Brands and companies operating in the same space as Ang Lifesciences India Limited include Exela Pharma, Gland Pharma, Luoxin Pharmaceutical Group and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Exela Pharma
|
Sterile injectable pharmaceuticals are manufactured alongside CDMO services. | Lenoir, United States, United States | 2005 |
Gland Pharma
|
Generic injectable drugs are manufactured across therapeutic segments. | Hyderabad, India, India | 1978 |
Luoxin Pharmaceutical Group
|
Developer and manufacturer of pharmaceutical products | Linyi, China, China | 2006 |
Summit Biosciences
|
Nasal spray drug products are developed, manufactured, and commercialized. | Lexington, United States, United States | 2008 |
August Bioservices
|
Diversified research services for clinical solutions are offered. | Nashville, United States, United States | 2017 |
ApiJect
|
Medicine injectors are manufactured by ApiJect for medical applications. | Stamford, United States, United States | 2015 |
Vetter Pharma
|
CDMO specializing in aseptically prefilled syringe systems, cartridges and vials. | Ravensburg, Germany, Germany | 1950 |
INCOG BioPharma Services
|
Injectable drug products are manufactured by this biopharma CDMO. | United States | 2020 |
Nitin Lifesciences
|
CMO of small volume parenteral injectables | Karnal, India, India | 1994 |
Business Activity of Ang Lifesciences India Limited
Ang Lifesciences India Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Ang Lifesciences India Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Ang Lifesciences India Limited
Ang Lifesciences India Limited is audited by M/s Khurana Sharma & Co. (ICAI peer reviewed, certificate valid till 2027-02-28) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s Khurana Sharma & Co. (ICAI peer reviewed, certificate valid till 2027-02-28) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Ang Lifesciences India Limited
Ang Lifesciences India Limited is currently managed by 6 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sukhpal Singh | Director | 02 May 2016 | 10 Years 2 Months | Current |
| Chetna | Director | 12 Oct 2021 | 4 Years 9 Months | Current |
|
Saruchi Gupta
Also directs:
Ang Lifesciences India Limited, Mansa Print And Publishers Limited, Baddi Agro Private Limited and 4 more
|
Whole-Time Director | 01 Apr 2011 | 15 Years 3 Months | Current |
|
Rajesh Gupta
Also directs:
Ang Lifesciences India Limited, Mansa Print And Publishers Limited, Ang Healthcare India Private Limited and 5 more
|
Managing Director | 14 Jun 2006 | 20 Years 1 Months | Current |
|
Harvinder Singh Dhami
Also directs:
Ang Lifesciences India Limited, Amanaya Ventures Limited
|
Director | 27 May 2024 | 2 Years 1 Months | Current |
|
Rohit Mittal
Also directs:
Ang Lifesciences India Limited, Mansa Print And Publishers Limited
|
Director | 11 Oct 2023 | 2 Years 9 Months | Current |
Financials of Ang Lifesciences India Limited FY 2026 filings available
Ang Lifesciences India Limited reported revenue of ₹92.89 Cr (up 0.05% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue from Operations | ₹92.89 Cr | ₹92.85 Cr | ₹146.11 Cr | ₹219.89 Cr | ₹354.3 Cr |
| Other Income | ₹54.4 Lakh | ₹2.01 Cr | ₹69.82 Lakh | ₹9.72 Cr | ₹90.13 Lakh |
| Total Income | ₹93.44 Cr | ₹94.86 Cr | ₹146.81 Cr | ₹229.61 Cr | ₹355.2 Cr |
| Cost of Materials Consumed | ₹57.34 Cr | ₹63.9 Cr | ₹102.79 Cr | ₹156.08 Cr | ₹234.65 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹3.2 Cr | -₹4.28 Cr | -₹7.67 Cr | -₹5.49 Cr | -₹6.67 Cr |
| Employee Benefit Expense | ₹16.54 Cr | ₹17.45 Cr | ₹19.35 Cr | ₹23.97 Cr | ₹21.29 Cr |
| Finance Costs | ₹7.93 Cr | ₹8.69 Cr | ₹10.96 Cr | ₹11.88 Cr | ₹8.91 Cr |
| Depreciation & Amortisation | ₹6.33 Cr | ₹6.76 Cr | ₹8.37 Cr | ₹9.35 Cr | ₹5.88 Cr |
| Other Expenses | ₹15.11 Cr | ₹18.04 Cr | ₹21.99 Cr | ₹31.2 Cr | ₹37.65 Cr |
| Total Expenses | ₹106.45 Cr | ₹110.56 Cr | ₹155.79 Cr | ₹226.99 Cr | ₹301.7 Cr |
| Profit Before Exceptional Items & Tax | -₹13.01 Cr | -₹15.7 Cr | -₹8.98 Cr | ₹2.63 Cr | ₹53.5 Cr |
| Exceptional Items | ₹0 | ₹0 | -₹1.74 Cr | ₹0 | ₹0 |
| Profit Before Tax | -₹13.01 Cr | -₹15.7 Cr | -₹10.71 Cr | ₹2.63 Cr | ₹53.5 Cr |
| Total Tax Expense | -₹1.93 Cr | -₹3.29 Cr | -₹57.06 Lakh | ₹2.89 Cr | ₹13.18 Cr |
| Net Profit | -₹11.08 Cr | -₹12.41 Cr | -₹10.14 Cr | -₹26.12 Lakh | ₹40.32 Cr |
| attributable to Owners | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| attributable to NCI | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹7.1 Lakh | ₹11.72 Lakh | ₹20.65 Lakh | ₹72.88 Lakh | ₹20.94 Lakh |
| Total Comprehensive Income | -₹11.01 Cr | -₹12.3 Cr | -₹9.94 Cr | ₹46.76 Lakh | ₹40.53 Cr |
| EBITDA (computed) | ₹1.25 Cr | -₹25.58 Lakh | ₹10.35 Cr | ₹23.86 Cr | ₹68.28 Cr |
| Basic EPS | ₹-8.43 | ₹-9.42 | ₹-7.61 | ₹0.00 | ₹39.09 |
| Diluted EPS | ₹-8.43 | ₹-9.42 | ₹-7.61 | ₹0.00 | ₹39.09 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Total Assets | ₹208.95 Cr | ₹229.59 Cr | ₹242.44 Cr | ₹279.7 Cr | ₹291.03 Cr |
| Non-current Assets | ₹59.59 Cr | ₹64.25 Cr | ₹63.5 Cr | ₹92.81 Cr | ₹98.22 Cr |
| Current Assets | ₹145.12 Cr | ₹161.03 Cr | ₹173.31 Cr | ₹185.19 Cr | ₹192.81 Cr |
| Property, Plant & Equipment | ₹50.61 Cr | ₹57.19 Cr | ₹58.4 Cr | ₹88.15 Cr | ₹92.61 Cr |
| Inventories | ₹46.26 Cr | ₹54.11 Cr | ₹47.77 Cr | ₹48.49 Cr | ₹36.96 Cr |
| Trade Receivables | ₹67.93 Cr | ₹66.54 Cr | ₹73.28 Cr | ₹83.15 Cr | ₹102.06 Cr |
| Cash & Equivalents | ₹49.39 Lakh | ₹15.73 Lakh | ₹31.85 Lakh | ₹32.42 Lakh | ₹34.6 Lakh |
| Equity (Net Worth) | ₹52.89 Cr | ₹63.98 Cr | ₹76.28 Cr | ₹86.22 Cr | ₹83.77 Cr |
| Equity Share Capital | ₹13.06 Cr | ₹13.06 Cr | ₹13.06 Cr | ₹13.06 Cr | ₹10.37 Cr |
| Borrowings (Non-current) | ₹4.62 Cr | ₹18.86 Cr | ₹13.95 Cr | ₹20.54 Cr | ₹21.64 Cr |
| Borrowings (Current) | ₹72.91 Cr | ₹61.57 Cr | ₹55.3 Cr | ₹49.44 Cr | ₹55.36 Cr |
| Total Debt (computed) | ₹77.53 Cr | ₹80.43 Cr | ₹69.24 Cr | ₹69.98 Cr | ₹77 Cr |
| Current Liabilities | ₹149.04 Cr | ₹143.44 Cr | ₹144.57 Cr | ₹162.28 Cr | ₹166.29 Cr |
| Total Liabilities | ₹156.06 Cr | ₹165.62 Cr | ₹166.16 Cr | ₹193.49 Cr | ₹207.26 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹11.03 Cr | -₹25.55 Lakh | -₹9.49 Cr | ₹26.38 Cr | ₹24.72 Cr |
| Investing Cash Flow | ₹1.05 Cr | -₹1.59 Cr | ₹19.89 Cr | -₹9.32 Cr | -₹44.41 Cr |
| Financing Cash Flow | -₹11.74 Cr | ₹1.68 Cr | -₹10.4 Cr | -₹17.07 Cr | ₹19.93 Cr |
| Capital Expenditure | ₹43.94 Lakh | ₹3.75 Cr | ₹5.57 Cr | ₹10.44 Cr | ₹41.34 Cr |
| Free Cash Flow (computed) | ₹10.59 Cr | -₹4.01 Cr | -₹15.06 Cr | ₹15.93 Cr | -₹16.63 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹1.04 Cr |
| Net Change in Cash | ₹33.68 Lakh | -₹16.12 Lakh | -₹57,000 | -₹2.18 Lakh | ₹23.5 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹23.5 Cr | ₹18.73 Cr | ₹26.05 Cr | ₹24.6 Cr | ₹16.82 Cr | ₹24.73 Cr | ₹32.88 Cr | ₹18.41 Cr |
| Other Income | ₹17.11 Lakh | ₹16.14 Lakh | ₹12.25 Lakh | ₹8.9 Lakh | ₹65.06 Lakh | -₹27.23 Lakh | ₹34.87 Lakh | ₹1.28 Cr |
| Total Income | ₹23.67 Cr | ₹18.89 Cr | ₹26.18 Cr | ₹24.69 Cr | ₹17.47 Cr | ₹24.46 Cr | ₹33.23 Cr | ₹19.69 Cr |
| Cost of Materials Consumed | ₹12.49 Cr | ₹10.37 Cr | ₹18.05 Cr | ₹16.43 Cr | ₹10.63 Cr | ₹16.9 Cr | ₹24.13 Cr | ₹12.24 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹1.02 Cr | ₹2.59 Cr | -₹20.93 Lakh | -₹20.42 Lakh | -₹17.59 Lakh | -₹85.42 Lakh | -₹2.68 Cr | -₹57.37 Lakh |
| Employee Benefit Expense | ₹3.59 Cr | ₹4.26 Cr | ₹4.32 Cr | ₹4.36 Cr | ₹4.17 Cr | ₹4.44 Cr | ₹4.58 Cr | ₹4.26 Cr |
| Finance Costs | ₹2.18 Cr | ₹1.93 Cr | ₹1.89 Cr | ₹1.94 Cr | ₹2.42 Cr | ₹2 Cr | ₹2.18 Cr | ₹2.08 Cr |
| Depreciation & Amortisation | ₹1.77 Cr | ₹1.51 Cr | ₹1.52 Cr | ₹1.53 Cr | ₹1.42 Cr | ₹1.96 Cr | ₹1.74 Cr | ₹1.63 Cr |
| Other Expenses | ₹3.72 Cr | ₹4.2 Cr | ₹3.81 Cr | ₹3.37 Cr | ₹2.9 Cr | ₹6.38 Cr | ₹4.57 Cr | ₹4.19 Cr |
| Total Expenses | ₹24.78 Cr | ₹24.86 Cr | ₹29.39 Cr | ₹27.42 Cr | ₹21.36 Cr | ₹30.84 Cr | ₹34.52 Cr | ₹23.84 Cr |
| Profit Before Exceptional Items & Tax | -₹1.1 Cr | -₹5.96 Cr | -₹3.21 Cr | -₹2.73 Cr | -₹3.89 Cr | -₹6.38 Cr | -₹1.29 Cr | -₹4.14 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹1.1 Cr | -₹5.96 Cr | -₹3.21 Cr | -₹2.73 Cr | -₹3.89 Cr | -₹6.38 Cr | -₹1.29 Cr | -₹4.14 Cr |
| Total Tax Expense | ₹27.73 Lakh | -₹1.21 Cr | -₹26.67 Lakh | -₹72.51 Lakh | -₹1.83 Cr | -₹1.19 Cr | ₹80.09 Lakh | -₹1.07 Cr |
| Net Profit | -₹1.38 Cr | -₹4.75 Cr | -₹2.95 Cr | -₹2.01 Cr | -₹2.06 Cr | -₹5.19 Cr | -₹2.09 Cr | -₹3.07 Cr |
| attributable to Owners | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| attributable to NCI | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹1.68 Lakh | ₹4.85 Lakh | ₹1.97 Lakh | ₹1.97 Lakh | ₹2.41 Lakh | ₹0 | ₹9.31 Lakh | ₹0 |
| Total Comprehensive Income | -₹1.36 Cr | -₹4.7 Cr | -₹2.93 Cr | -₹1.99 Cr | -₹2.04 Cr | -₹5.19 Cr | -₹2 Cr | -₹3.07 Cr |
| EBITDA (computed) | ₹2.84 Cr | -₹2.53 Cr | ₹20.24 Lakh | ₹73.34 Lakh | -₹4.8 Lakh | -₹2.42 Cr | ₹2.64 Cr | -₹42.48 Lakh |
| Basic EPS | ₹-1.07 | ₹-3.60 | ₹-2.24 | ₹-1.52 | ₹-1.56 | ₹-3.98 | ₹-1.53 | ₹-2.35 |
| Diluted EPS | ₹-1.07 | ₹-3.60 | ₹-2.24 | ₹-1.52 | ₹-1.56 | ₹-3.98 | ₹-1.53 | ₹-2.35 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical | ₹22.8 Cr | ₹3.08 Cr | ₹189.91 Cr | ₹124.58 Cr |
| Printing & Publishers | ₹1.73 Cr | -₹1.88 Cr | ₹29.88 Cr | ₹27.68 Cr |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical | ₹91.6 Cr | ₹1.26 Cr | - | - |
| Printing & Publishers | ₹4.86 Cr | -₹5.85 Cr | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹91.6 Cr | ₹89.91 Cr | ₹131.37 Cr | ₹207.01 Cr | ₹348.67 Cr | ₹154.38 Cr | ₹126.83 Cr | ₹121.7 Cr |
| Other Income | ₹72.66 Lakh | ₹2.44 Cr | ₹83.52 Lakh | ₹9.84 Cr | ₹95.15 Lakh | ₹55.59 Lakh | ₹41.97 Lakh | ₹23.27 Lakh |
| Total Income | ₹92.33 Cr | ₹92.35 Cr | ₹132.2 Cr | ₹216.85 Cr | ₹349.62 Cr | - | - | - |
| Cost of Materials Consumed | ₹55.08 Cr | ₹63.98 Cr | ₹93.93 Cr | ₹151.12 Cr | ₹234.49 Cr | ₹108.26 Cr | ₹89.56 Cr | ₹88.89 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹3.21 Cr | -₹3.39 Cr | -₹6.74 Cr | -₹4.22 Cr | -₹4.47 Cr | -₹4.3 Cr | -₹58.77 Lakh | -₹1.05 Cr |
| Employee Benefit Expense | ₹14.35 Cr | ₹14.45 Cr | ₹15.9 Cr | ₹20.27 Cr | ₹18.32 Cr | ₹13.68 Cr | ₹7.94 Cr | ₹6.39 Cr |
| Finance Costs | ₹6.45 Cr | ₹7.3 Cr | ₹9.33 Cr | ₹10.32 Cr | ₹7.85 Cr | ₹2.97 Cr | ₹2.87 Cr | ₹2.34 Cr |
| Depreciation & Amortisation | ₹6.08 Cr | ₹6.27 Cr | ₹7.75 Cr | ₹8.52 Cr | ₹5.12 Cr | - | - | - |
| Other Expenses | ₹12.36 Cr | ₹16.68 Cr | ₹19.15 Cr | ₹28.76 Cr | ₹35.25 Cr | ₹22.88 Cr | ₹17.84 Cr | ₹16.13 Cr |
| Total Expenses | ₹97.52 Cr | ₹105.29 Cr | ₹139.34 Cr | ₹214.78 Cr | ₹296.56 Cr | ₹144.8 Cr | ₹118.84 Cr | ₹113.82 Cr |
| Profit Before Exceptional Items & Tax | -₹5.19 Cr | -₹12.94 Cr | -₹7.13 Cr | ₹2.07 Cr | ₹53.06 Cr | - | - | - |
| Exceptional Items | ₹0 | ₹0 | -₹1.74 Cr | ₹0 | ₹0 | - | - | - |
| Profit Before Tax | -₹5.19 Cr | -₹12.94 Cr | -₹8.87 Cr | ₹2.07 Cr | ₹53.06 Cr | ₹10.14 Cr | ₹8.41 Cr | ₹8.11 Cr |
| Total Tax Expense | -₹46.45 Lakh | -₹2.59 Cr | -₹21.93 Lakh | ₹2.73 Cr | ₹13.35 Cr | ₹3.11 Cr | ₹2.31 Cr | ₹2.46 Cr |
| Net Profit | -₹4.73 Cr | -₹10.34 Cr | -₹8.65 Cr | -₹66.22 Lakh | ₹39.71 Cr | ₹7.03 Cr | ₹6.1 Cr | ₹5.65 Cr |
| Other Comprehensive Income | ₹13.42 Lakh | ₹7.87 Lakh | ₹18.62 Lakh | ₹71.63 Lakh | ₹20.94 Lakh | - | - | - |
| Total Comprehensive Income | -₹4.59 Cr | -₹10.26 Cr | -₹8.46 Cr | ₹5.41 Lakh | ₹39.92 Cr | - | - | - |
| EBITDA (computed) | ₹7.34 Cr | ₹63.65 Lakh | ₹9.95 Cr | ₹20.91 Cr | ₹66.03 Cr | - | - | - |
| Basic EPS | ₹-3.52 | ₹-7.86 | ₹-6.48 | ₹0.04 | ₹38.51 | - | - | - |
| Diluted EPS | ₹-3.52 | ₹-7.86 | ₹-6.48 | ₹0.04 | ₹38.51 | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹189.91 Cr | ₹208.67 Cr | ₹217.43 Cr | ₹252.51 Cr | ₹268.68 Cr | ₹143.65 Cr | ₹94.08 Cr | ₹80.9 Cr |
| Non-current Assets | ₹52.71 Cr | ₹57.87 Cr | ₹57.35 Cr | ₹82.6 Cr | ₹87.12 Cr | ₹27.78 Cr | ₹21.36 Cr | ₹20.94 Cr |
| Current Assets | ₹132.97 Cr | ₹146.57 Cr | ₹158.37 Cr | ₹168.21 Cr | ₹181.57 Cr | ₹115.87 Cr | ₹72.71 Cr | ₹59.96 Cr |
| Property, Plant & Equipment | ₹47.05 Cr | ₹52.63 Cr | ₹53.35 Cr | ₹78.68 Cr | ₹82.32 Cr | - | - | - |
| Inventories | ₹33 Cr | ₹37.84 Cr | ₹34.24 Cr | ₹37.39 Cr | ₹29.17 Cr | ₹19.26 Cr | ₹10 Cr | ₹6.54 Cr |
| Trade Receivables | ₹65.35 Cr | ₹64.96 Cr | ₹69.27 Cr | ₹78.11 Cr | ₹98.99 Cr | - | - | - |
| Cash & Equivalents | ₹28.3 Lakh | ₹7.91 Lakh | ₹8.53 Lakh | ₹20.14 Lakh | ₹28.51 Lakh | ₹3.86 Cr | ₹3.58 Cr | ₹4.37 Cr |
| Equity (Net Worth) | ₹62.22 Cr | ₹66.81 Cr | ₹77.07 Cr | ₹85.54 Cr | ₹83.48 Cr | - | - | - |
| Equity Share Capital | ₹13.06 Cr | ₹13.06 Cr | ₹13.06 Cr | ₹13.06 Cr | ₹10.37 Cr | - | - | - |
| Borrowings (Non-current) | ₹84.46 Lakh | ₹13.34 Cr | ₹6.97 Cr | ₹10.06 Cr | ₹12.01 Cr | - | - | - |
| Borrowings (Current) | ₹64.13 Cr | ₹54.47 Cr | ₹48.8 Cr | ₹42.69 Cr | ₹48.99 Cr | - | - | - |
| Total Debt (computed) | ₹64.97 Cr | ₹67.8 Cr | ₹55.77 Cr | ₹52.75 Cr | ₹60.99 Cr | - | - | - |
| Current Liabilities | ₹124.58 Cr | ₹125.37 Cr | ₹125.9 Cr | ₹146.36 Cr | ₹153.92 Cr | ₹91.56 Cr | ₹50.9 Cr | ₹42.4 Cr |
| Total Liabilities | ₹127.69 Cr | ₹141.86 Cr | ₹140.35 Cr | ₹166.97 Cr | ₹185.2 Cr | - | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹13.72 Cr | -₹2.29 Cr | -₹13.13 Cr | ₹26.01 Cr | ₹27.39 Cr |
| Investing Cash Flow | -₹3.33 Cr | -₹1.63 Cr | ₹20.02 Cr | -₹9.35 Cr | -₹42.5 Cr |
| Financing Cash Flow | -₹10.19 Cr | ₹3.92 Cr | -₹7 Cr | -₹16.75 Cr | ₹15.29 Cr |
| Capital Expenditure | ₹4.13 Cr | ₹4.12 Cr | ₹5.44 Cr | ₹10.43 Cr | ₹39.35 Cr |
| Free Cash Flow (computed) | ₹9.59 Cr | -₹6.41 Cr | -₹18.57 Cr | ₹15.58 Cr | -₹11.96 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹1.04 Cr |
| Net Change in Cash | ₹20.39 Lakh | -₹62,000 | -₹11.6 Lakh | -₹8.37 Lakh | ₹17.4 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹22.8 Cr | ₹18.3 Cr | ₹25.97 Cr | ₹24.53 Cr | ₹17.67 Cr | ₹23.91 Cr | ₹32.16 Cr | ₹16.18 Cr |
| Other Income | ₹18.78 Lakh | ₹15.76 Lakh | ₹20.78 Lakh | ₹17.34 Lakh | ₹75.03 Lakh | -₹2.83 Lakh | ₹36.36 Lakh | ₹1.36 Cr |
| Total Income | ₹22.99 Cr | ₹18.46 Cr | ₹26.18 Cr | ₹24.71 Cr | ₹18.42 Cr | ₹23.88 Cr | ₹32.52 Cr | ₹17.54 Cr |
| Cost of Materials Consumed | ₹11 Cr | ₹10.61 Cr | ₹17.01 Cr | ₹16.45 Cr | ₹11.57 Cr | ₹16.85 Cr | ₹24.18 Cr | ₹11.37 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹1.94 Cr | ₹2.09 Cr | -₹56.85 Lakh | -₹25.3 Lakh | ₹26.01 Lakh | -₹71.44 Lakh | -₹2.42 Cr | -₹51.48 Lakh |
| Employee Benefit Expense | ₹3.32 Cr | ₹3.67 Cr | ₹3.86 Cr | ₹3.49 Cr | ₹3.44 Cr | ₹3.72 Cr | ₹3.79 Cr | ₹3.5 Cr |
| Finance Costs | ₹1.65 Cr | ₹1.61 Cr | ₹1.59 Cr | ₹1.61 Cr | ₹2.05 Cr | ₹1.71 Cr | ₹1.87 Cr | ₹1.67 Cr |
| Depreciation & Amortisation | ₹1.73 Cr | ₹1.45 Cr | ₹1.45 Cr | ₹1.45 Cr | ₹1.3 Cr | ₹1.84 Cr | ₹1.62 Cr | ₹1.51 Cr |
| Other Expenses | ₹1.92 Cr | ₹4 Cr | ₹3.45 Cr | ₹2.99 Cr | ₹2.76 Cr | ₹6.03 Cr | ₹4.15 Cr | ₹3.74 Cr |
| Total Expenses | ₹21.56 Cr | ₹23.44 Cr | ₹26.8 Cr | ₹25.73 Cr | ₹21.38 Cr | ₹29.44 Cr | ₹33.19 Cr | ₹21.28 Cr |
| Profit Before Exceptional Items & Tax | ₹1.43 Cr | -₹4.98 Cr | -₹61.68 Lakh | -₹1.03 Cr | -₹2.96 Cr | -₹5.56 Cr | -₹66.79 Lakh | -₹3.75 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹1.43 Cr | -₹4.98 Cr | -₹61.68 Lakh | -₹1.03 Cr | -₹2.96 Cr | -₹5.56 Cr | -₹66.79 Lakh | -₹3.75 Cr |
| Total Tax Expense | ₹32.71 Lakh | -₹73.53 Lakh | ₹18.31 Lakh | -₹23.94 Lakh | -₹1.02 Cr | -₹99.69 Lakh | ₹40.6 Lakh | -₹98.34 Lakh |
| Net Profit | ₹1.1 Cr | -₹4.24 Cr | -₹79.99 Lakh | -₹78.73 Lakh | -₹1.94 Cr | -₹4.57 Cr | -₹1.07 Cr | -₹2.77 Cr |
| Other Comprehensive Income | ₹7.52 Lakh | ₹1.96 Lakh | ₹1.97 Lakh | ₹1.97 Lakh | -₹1.44 Lakh | ₹0 | ₹9.31 Lakh | ₹0 |
| Total Comprehensive Income | ₹1.18 Cr | -₹4.22 Cr | -₹78.02 Lakh | -₹76.76 Lakh | -₹1.95 Cr | -₹4.57 Cr | -₹98.08 Lakh | -₹2.77 Cr |
| EBITDA (computed) | ₹4.81 Cr | -₹1.92 Cr | ₹2.42 Cr | ₹2.03 Cr | ₹38.93 Lakh | -₹2.01 Cr | ₹2.82 Cr | -₹56.85 Lakh |
| Basic EPS | ₹0.90 | ₹-3.23 | ₹-0.60 | ₹-0.59 | ₹-1.50 | ₹-3.50 | ₹-0.75 | ₹-2.12 |
| Diluted EPS | ₹0.90 | ₹-3.23 | ₹-0.60 | ₹-0.59 | ₹-1.50 | ₹-3.50 | ₹-0.75 | ₹-2.12 |
Shareholding Pattern of Ang Lifesciences India Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 70.60%, retail and other public shareholders hold 29.40% of Ang Lifesciences India Limited. The company had 5,952 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% |
| Public | 29.40% | 29.40% | 29.40% | 29.40% | 29.40% | 29.40% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 70.60% | 70.60% | 70.60% |
| Public | 29.40% | 29.40% | 29.40% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | - |
Group Structure of Ang Lifesciences India Limited
Ang Lifesciences India Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Ang Lifesciences India Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Mansa Print And Publishers Limited | U22110PB2003PLC054383 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Ang Lifesciences India Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Mar 2024 | Others | ₹5 Cr | Open |
| 19 Oct 2022 | Others | ₹5 Cr | Open |
| 31 Mar 2022 | Others | ₹18 Lakh | Open |
| 07 Jan 2022 | Others | ₹1.2 Cr | Open |
| 06 Jan 2022 | Canara Bank | ₹10 Cr | Open |
Total charge records: 28 View all charges
Employees and EPFO Compliance at Ang Lifesciences India Limited
Ang Lifesciences India Limited has a workforce of 459 employees as of Feb 17, 2025.
Employee and EPFO history for Ang Lifesciences India Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Ang Lifesciences India Limited
GST registrations and filing compliance for Ang Lifesciences India Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Ang Lifesciences India Limited
Credit ratings, litigation, and regulatory alerts for Ang Lifesciences India Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Ang Lifesciences India Limited
MSME payment history for Ang Lifesciences India Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Ang Lifesciences India Limited
Corporate group structure for Ang Lifesciences India Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Ang Lifesciences India Limited
MCA filings and documents for Ang Lifesciences India Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Ang Lifesciences India Limited
Recent News on Ang Lifesciences India Limited
Frequently Asked Questions about Ang Lifesciences India Limited
Ang Lifesciences India Limited is an active public limited company in the pharma sector based in Amritsar, Punjab, India. It was incorporated on 14 June 2006 (20+ years old) and is registered under CIN L24230PB2006PLC030341. Listed on BSE: 540694. The company has 459 employees.
Ang Lifesciences India Limited reported revenue of ₹92.89 Cr for FY 2026 (up 0.05% YoY) based on consolidated BSE filings.
The current directors of Ang Lifesciences India Limited are:
- Sukhpal Singh - Director
- Chetna - Director
- Saruchi Gupta - Whole-Time Director
- Rajesh Gupta - Managing Director
- Harvinder Singh Dhami - Director
- Rohit Mittal - Director
The primary industry of Ang Lifesciences India Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Ang Lifesciences India Limited is listed on BSE with code 540694.
Ang Lifesciences India Limited can be reached at the registered office: Darbara Complex Sco 113 First Floor District Shopping Centre B Block Ranjit, Avenue, Amritsar, Punjab, India – 143001, or through the website anglifesciences.com.